These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 29091159)

  • 1. Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer.
    Aguiar PN; Barreto CMN; Gutierres BS; Tadokoro H; Lopes GL
    Einstein (Sao Paulo); 2017; 15(3):349-354. PubMed ID: 29091159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
    Zheng HR; Wen F; Wu YF; Wheeler JRC; Li Q
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27145493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
    Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
    Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
    Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
    Woods BS; Sideris E; Sydes MR; Gannon MR; Parmar MKB; Alzouebi M; Attard G; Birtle AJ; Brock S; Cathomas R; Chakraborti PR; Cook A; Cross WR; Dearnaley DP; Gale J; Gibbs S; Graham JD; Hughes R; Jones RJ; Laing R; Mason MD; Matheson D; McLaren DB; Millman R; O'Sullivan JM; Parikh O; Parker CC; Peedell C; Protheroe A; Ritchie AWS; Robinson A; Russell JM; Simms MS; Srihari NN; Srinivasan R; Staffurth JN; Sundar S; Thalmann GN; Tolan S; Tran ATH; Tsang D; Wagstaff J; James ND; Sculpher MJ
    Eur Urol Oncol; 2018 Dec; 1(6):449-458. PubMed ID: 31158087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
    Dyer M; Rinaldi F; George E; Adler AI
    Lancet Oncol; 2012 Aug; 13(8):762-3. PubMed ID: 23024987
    [No Abstract]   [Full Text] [Related]  

  • 7. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective.
    Teoh JY; Ng CF; Poon DM
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():5-8. PubMed ID: 30489034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
    Lu L; Peters J; Roome C; Stein K
    BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
    Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
    Ramamurthy C; Handorf EA; Correa AF; Beck JR; Geynisman DM
    Urol Oncol; 2019 Oct; 37(10):688-695. PubMed ID: 31399302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
    Amato RJ; Teh BS; Henary H; Khan M; Saxena S
    Urol Oncol; 2009; 27(2):165-9. PubMed ID: 18367115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review.
    Kyriakopoulos CE; Liu G
    Cancer J; 2016; 22(5):322-325. PubMed ID: 27749324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
    Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
    J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
    Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S
    J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO].
    Ohlmann CH; Gschwend J; Miller K
    Urologe A; 2016 Sep; 55(9):1164-72. PubMed ID: 27431813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
    Iannazzo S; Pradelli L; Carsi M; Perachino M
    Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
    Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of metastatic hormone-sensitive prostate cancer.
    Bernard B; Sweeney CJ
    Curr Urol Rep; 2015 Mar; 16(3):14. PubMed ID: 25677237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
    Zhang P; Wen F; Fu P; Yang Y; Li Q
    Tumori; 2017 Jul; 103(4):380-386. PubMed ID: 28009424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.